Reviewing Bristol-Myers’ $90 Billion Acquisition of Celgene
Large-scale M&A is nothing new to Wall Street, especially in the pharmaceutical industry. However, mega deals are often fraught with risks, so when a dividend stock announces an enormous purchase investors understandably get nervous. On January 3, 2019, Bristol-Myers Squibb (BMY) announced it will be buying biotech giant Celgene (CELG) in a $74 billion deal ($90 billion [...]